Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer

Abstract

Several recent trials have demonstrated that neoadjuvant chemotherapy can allow more patients to successfully undergo breast-conserving treatment (BCT), and does not confer a survival disadvantage compared with standard adjuvant chemotherapy. In addition, the pathological response of primary breast tumors to neoadjuvant chemotherapy appears to be a surrogate marker for patient outcome.

In our series, during the period from May 1995 to December 2000, 86 patients with tumors between 3.1 and 6.0 cm in diameter received epirubicin-based neoadjuvant chemotherapy. There were 55 (64.0%) responders and ultimately 64 patients (74.4%) were treated with BCT. The margin positive rate was 14.1% (9/64), similar to the rate after BCT for early-stage breast cancers, the largest diameter of which was smaller than 3 cm. At a median follow-up of 30 months, only 3 patients in the BCT group have developed local recurrence; the local recurrence rate appears to be comparable to that after BCT for early stage breast cancers. Long term follow-up is required, however, to establish whether this procedure is a safe alternative to mastectomy for patients with large breast cancers.

This is a preview of subscription content, log in to check access.

References

  1. 1)

    Fisher B, Bryant J, Wolmark N,et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16: 2672–2685, 1998.

  2. 2)

    Calais G, Berger C, Descamps P,et al: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.Cancer 74: 1283–1288, 1994.

  3. 3)

    Schwartz GF, Birchansky CA, Komaraicky LT,et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.Cancer 73: 362–369, 1994.

  4. 4)

    Veronesi U, Bonadonna G, Zurrida S,et al: Conservation surgery after primary chemotherapy in large carcinomas of the breast.Ann Surg 222: 612–618, 1995.

  5. 5)

    Touboul E, Lefranc JP, Blondon J,et al: Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced noninflammatory breast cancer.Radiother Oncol 42: 219–229, 1997.

  6. 6)

    Merajver SD, Weber BL, Cody R,et al: Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience.J Clin Oncol 15: 2873–2881, 1997.

  7. 7)

    Bonadonna G, Valagussa P, Brambilla C,et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute.J Clin Oncol 16: 93–100, 1998.

  8. 8)

    Danforth DN Jr, Zujewski J, O’Shaughnessy J,et al: Selection of local therapy after neoadjuvant chemotherapy in patients with stage III A, B breast cancer.Ann Surg Oncol 5: 150–158, 1998.

  9. 9)

    Mauriac L, MacGrogan G, Avril A,et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up.Ann Oncol 10: 47–52, 1999.

  10. 10)

    Kuerer HM, Newman LA, Smith TL,et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol 17: 460–469, 1999.

  11. 11)

    Bellino R, Cortese P, Danese S,et al: Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.Anticancer Res 20: 4825–4828, 2000.

  12. 12)

    Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.Oncol 11 (supp 8): 15–18, 1997.

  13. 13)

    Scholl SM, Fourquet A, Asselain B,et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial: S6.Eur J Cancer 30A: 645–652, 1994.

  14. 14)

    Makris A, Powles TJ, Ashley SE,et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.Ann Oncol 9: 1179–1184, 1998.

  15. 15)

    Noguchi S, Koyama H, Kasugai T,et al: A case-control study on risk factors for local recurrences or distant metastases in breast cancer patients treated with breast-conserving surgery.Oncol 54: 468–474, 1997.

  16. 16)

    Hunt KK, Buzdar AU: Breast conservation and tumor down-staging. In: Singletary S, ed. Breast Cancer. New York: Springer-Verlag, 196–205, 1998.

  17. 17)

    El-Didi MH, Moneer MM, Khaled HM,et al: Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management.Surg Today 30: 249–254, 2000.

  18. 18)

    Huber S, Wagner M, Zuna I,et al: Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy.Anticancer Res 20: 553–558, 2000.

  19. 19)

    Esserman L, Hylton N, Yassa L,et al: Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.J Clin Oncol 17: 110–119, 1999.

  20. 20)

    Akashi-Tanaka S, Fukutomi T, Miyakawa K,et al: Contrast-enhanced computed tomography for diagnosing the intraductal component and small invasive foci of breast cancer.Breast Cancer 8: 10–15, 2001.

  21. 21)

    Singletary SE, Dhingra K, Yu DH: New strategies in locally advanced breast cancer.Cancer Treat Res 90: 253–271, 1997.

  22. 22)

    Ellis P, Smith I, Ashley S,et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.J Clin Oncol 16: 107–114, 1998.

  23. 23)

    Kuerer HM, Hunt KK, Newman LAet al: Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues.J Am Coll Surg 190: 350–363, 2000.

  24. 24)

    Nishimura R, Koyama H, Kasumi Fet al: A case control study on risk factors involved in inflammatory breast recurrence after breast-conserving surgery.Oncol 55: 391–399, 1998.

  25. 25)

    Kuerer HM, Sahin AA, Hunt KKet al: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.Ann Surg 230: 72–78, 1999.

  26. 26)

    Cox CE, Haddad F, Bass Set al: Lymphatic mapping in the treatment of breast cancer.Oncology 12: 1283–1298, 1998.

  27. 27)

    Motomura K, Inaji H, Komoike Y,et al: Gamma probe and ultrasonographically -guided fine needle aspiration biopsy of sentinel lymph node in breast cancer patients.EurJ Surg Oncol 27: 141–145, 2001.

  28. 28)

    Powles TJ, Hickish TF, Makris HA,et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.J Clin Oncol 13: 547–552, 1995.

Download references

Author information

Correspondence to Hideo Inaji or Yoshifumi Komoike or Kazuyoshi Motomura or Tsutomu Kasugai or Yuka Sawai or Masahiko Koizumi or Takayuki Nose or Hiroki Koyama.

Additional information

Reprint requests to Hideo Inaji, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.

About this article

Cite this article

Inaji, H., Komoike, Y., Motomura, K. et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast Cancer 9, 20 (2002). https://doi.org/10.1007/BF02967542

Download citation

Key words

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Breast-conserving treatment
  • Local recurrence